All bodily cells contain the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is located in the cytoplasm. It is a maintenance enzyme that is essential for preventing cellular damage caused by ROS (reactive oxygen species). By offering substrates to stop oxidative damage, it achieves this.
Due to their function in the transport of oxygen and the incapacity to replenish cellular components as adult cells, red cells are especially prone to ROS. In periods of heightened Ros generation, inherited G6PD deficits can cause severe hemolytic anemia.
Stress, exposure to foods like fava beans that are strong in oxidative chemicals, or specific drugs could all contribute to this. In individuals with G6PD deficiency, anti-malarial medications, in particular, show a substantial correlation with the development of hemolytic anemia.
The drugs listed below are more frequently prescribed in the U.s and have been documented to cause hemolytic crises in people with G6PD deficit; nevertheless, the Italian G6PD Deficit Association has released a more extensive list of drugs to avoid.
In patients with G6PD deficiency, common drugs that should be avoided or taken with caution include:
The most prevalent human enzyme deficiency, known as G6PD, affects around 400 million individuals worldwide. Because of X-linked heredity, men would be more frequently impacted than women. Areas that are tropical, as well as subtropical, are where it is most common.
It’s interesting to note that there is evidence that G6PD deficit protects against simple instances of malaria but not serious conditions. Malaria and G6PD deficiency have protective mechanism that is currently being researched.
Individuals of African, Asian, or Mediterranean heritage are more likely to have a G6PD deficit than those of other ethnicities, possibly because of the condition’s potential to protect against malaria.
Anatomy
Pathophysiology
The pentose phosphate route employs glucose-6-phosphate to transform nicotinamide adenine dinucleotide phosphate (NADP) into its reduced form, NADPH. The rate-limiting initial step of this system uses G6PD as a catalyst.
When oxygen-free electrons attack the intracellular structures of RBC cells, NADPH plays a crucial protective role.
This is accomplished by acting as a substrate for the glutathione reductase enzyme. RBCs have a lower capacity for repair after they reach maturity. Thus, reduced glutathione can be employed to avoid injury to cellular components and turn hydrogen peroxide into water.
Etiology
The G6PD enzyme is encoded by the Gd gene. Since this gene is on the long arm of chromosome X, it is inherited exclusively through chromosome X. A lack of G6PD may result from mutations that alter the structure of the protein and, as a result, decrease its activity or the quantity of enzyme generated.
There are now 186 known human G6PD alterations, the majority of which are single-nucleotide point mutations. None of the human mutation types that affect G6PD result in its total inactivation since doing so would be fatal to an embryo.
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK470315/
News
Vaping’s ‘95% Safer’ Claim Debated for Youth Health
Posted on
News
Google DeepMind’s AI Revolutionizes the Search for Disease Genes
Posted on
News
Mosquitoes Pose New Challenge to Public Health
Posted on
News
3D-Printed e3-skin Redefines Wearable Health Monitoring
All bodily cells contain the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is located in the cytoplasm. It is a maintenance enzyme that is essential for preventing cellular damage caused by ROS (reactive oxygen species). By offering substrates to stop oxidative damage, it achieves this.
Due to their function in the transport of oxygen and the incapacity to replenish cellular components as adult cells, red cells are especially prone to ROS. In periods of heightened Ros generation, inherited G6PD deficits can cause severe hemolytic anemia.
Stress, exposure to foods like fava beans that are strong in oxidative chemicals, or specific drugs could all contribute to this. In individuals with G6PD deficiency, anti-malarial medications, in particular, show a substantial correlation with the development of hemolytic anemia.
The drugs listed below are more frequently prescribed in the U.s and have been documented to cause hemolytic crises in people with G6PD deficit; nevertheless, the Italian G6PD Deficit Association has released a more extensive list of drugs to avoid.
In patients with G6PD deficiency, common drugs that should be avoided or taken with caution include:
The most prevalent human enzyme deficiency, known as G6PD, affects around 400 million individuals worldwide. Because of X-linked heredity, men would be more frequently impacted than women. Areas that are tropical, as well as subtropical, are where it is most common.
It’s interesting to note that there is evidence that G6PD deficit protects against simple instances of malaria but not serious conditions. Malaria and G6PD deficiency have protective mechanism that is currently being researched.
Individuals of African, Asian, or Mediterranean heritage are more likely to have a G6PD deficit than those of other ethnicities, possibly because of the condition’s potential to protect against malaria.
The pentose phosphate route employs glucose-6-phosphate to transform nicotinamide adenine dinucleotide phosphate (NADP) into its reduced form, NADPH. The rate-limiting initial step of this system uses G6PD as a catalyst.
When oxygen-free electrons attack the intracellular structures of RBC cells, NADPH plays a crucial protective role.
This is accomplished by acting as a substrate for the glutathione reductase enzyme. RBCs have a lower capacity for repair after they reach maturity. Thus, reduced glutathione can be employed to avoid injury to cellular components and turn hydrogen peroxide into water.
The G6PD enzyme is encoded by the Gd gene. Since this gene is on the long arm of chromosome X, it is inherited exclusively through chromosome X. A lack of G6PD may result from mutations that alter the structure of the protein and, as a result, decrease its activity or the quantity of enzyme generated.
There are now 186 known human G6PD alterations, the majority of which are single-nucleotide point mutations. None of the human mutation types that affect G6PD result in its total inactivation since doing so would be fatal to an embryo.
https://www.ncbi.nlm.nih.gov/books/NBK470315/
medtigo
Glucose-6-phosphate dehydrogenase deficiency
Updated :
August 30, 2023
All bodily cells contain the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is located in the cytoplasm. It is a maintenance enzyme that is essential for preventing cellular damage caused by ROS (reactive oxygen species). By offering substrates to stop oxidative damage, it achieves this.
Due to their function in the transport of oxygen and the incapacity to replenish cellular components as adult cells, red cells are especially prone to ROS. In periods of heightened Ros generation, inherited G6PD deficits can cause severe hemolytic anemia.
Stress, exposure to foods like fava beans that are strong in oxidative chemicals, or specific drugs could all contribute to this. In individuals with G6PD deficiency, anti-malarial medications, in particular, show a substantial correlation with the development of hemolytic anemia.
The drugs listed below are more frequently prescribed in the U.s and have been documented to cause hemolytic crises in people with G6PD deficit; nevertheless, the Italian G6PD Deficit Association has released a more extensive list of drugs to avoid.
In patients with G6PD deficiency, common drugs that should be avoided or taken with caution include:
The most prevalent human enzyme deficiency, known as G6PD, affects around 400 million individuals worldwide. Because of X-linked heredity, men would be more frequently impacted than women. Areas that are tropical, as well as subtropical, are where it is most common.
It’s interesting to note that there is evidence that G6PD deficit protects against simple instances of malaria but not serious conditions. Malaria and G6PD deficiency have protective mechanism that is currently being researched.
Individuals of African, Asian, or Mediterranean heritage are more likely to have a G6PD deficit than those of other ethnicities, possibly because of the condition’s potential to protect against malaria.
The pentose phosphate route employs glucose-6-phosphate to transform nicotinamide adenine dinucleotide phosphate (NADP) into its reduced form, NADPH. The rate-limiting initial step of this system uses G6PD as a catalyst.
When oxygen-free electrons attack the intracellular structures of RBC cells, NADPH plays a crucial protective role.
This is accomplished by acting as a substrate for the glutathione reductase enzyme. RBCs have a lower capacity for repair after they reach maturity. Thus, reduced glutathione can be employed to avoid injury to cellular components and turn hydrogen peroxide into water.
The G6PD enzyme is encoded by the Gd gene. Since this gene is on the long arm of chromosome X, it is inherited exclusively through chromosome X. A lack of G6PD may result from mutations that alter the structure of the protein and, as a result, decrease its activity or the quantity of enzyme generated.
There are now 186 known human G6PD alterations, the majority of which are single-nucleotide point mutations. None of the human mutation types that affect G6PD result in its total inactivation since doing so would be fatal to an embryo.
https://www.ncbi.nlm.nih.gov/books/NBK470315/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
